

**PATENT ASSIGNMENT**

Electronic Version v1.1  
 Stylesheet Version v1.1

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	EXECUTIVE ORDER 9424, CONFIRMATORY LICENSE
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
WASHINGTON UNIVERSITY	03/14/1995
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	National Institutes of Health (NIH), U.S. Dept. of Health and Human Services (DHHS), U.S. Government
<b>Street Address:</b>	NIH Division of Extramural Inventions and Technology Resources (DEITR)
<b>Internal Address:</b>	6705 Rockledge Drive, Suite 310, MSC 7980
<b>City:</b>	Bethesda
<b>State/Country:</b>	MARYLAND
<b>Postal Code:</b>	20892-7980
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
Application Number:	08376889
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(301)480-0272
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
<b>Email:</b>	edison@nih.gov
<b>Correspondent Name:</b>	Director, DEITR
<b>Address Line 1:</b>	NIH, 6705 Rockledge Drive, Suite 310
<b>Address Line 2:</b>	MSC 7980
<b>Address Line 4:</b>	Bethesda, MARYLAND 20892-7980
<b>NAME OF SUBMITTER:</b>	Director, DEITR, NIH
<b>Total Attachments: 1</b> source=08376889#page1.tif	

LICENSE TO THE UNITED STATES GOVERNMENT

This instrument confers to the United States Government, as represented by the National Institutes of Health, a nonexclusive, nontransferable, irrevocable, paid-up license to practice or have practiced on its behalf throughout the world the following subject invention, patent application and any and all divisions or continuations, and any resulting patent or reissues which may be granted thereon:

Invention Title: Anti-Neoplastic, Anti-Viral and Ribonucleotide Reductase Activity Affecting Pharmaceutical Compositions and Methods of Treatment

Inventor(s): Raymond J. Bergeron, Jr.

Patent Application

Serial No. 08/376,889

Filing Date: January 20, 1995

Title: Anti-Neoplastic, Anti-Viral and Ribonucleotide Reductase Activity Affecting Pharmaceutical Compositions and Methods of Treatment

Country, if other than  
United States: None

This subject invention was conceived or first actually reduced to practice in performance of a government-funded project, National Institutes of Health Grant No. R01 AM29936.

Principal rights to this subject invention have been left with the Licensor: UNIVERSITY OF FLORIDA, subject to the provisions of 37 CFR 401 and 45 CFR 8.

Signed this 14th day of March, 1995.

UNIVERSITY OF FLORIDA  
DIVISION OF SPONSORED RESEARCH

By 

Dr. Susan D. Wray  
Director for Patent, Copyright  
and Technology Licensing

PATENT

RECORDED: 01/08/2009

REEL: 022074 FRAME: 0513